|
 |
|
陝西麥科奧特醫藥科技股份有限公司 |
Code: |
02335 |
| SHAANXI MICOT PHARMACEUTICAL TECHNOLOGY CO., LTD. |
Website: |
http://www.micot.cn |
| Chairman |
|
Wang Bing |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman & Chief Executive Officer: Wang Bing
Executive Director: Yu Weiping
Non-executive Director: Wang Mei, You Xiangdong, Song Gaoguang, Wang Nayi
Independent Non-executive Director: Xiangli Liuxu, Zhang Wenqiang, Wang Kaifeng.
|
| Principle Business |
|
The Group is principally engaged in biopharmaceutical business, focusing on the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases, cardiovascular and cerebrovascular diseases. |
| Related Indexes | | Hang Seng Healthcare Index | Hang Seng Healthcare Industry Index | | Hang Seng Composite SmallCap Index | Hang Seng Composite Index |
|
| Major Shareholders |
| Wang Bing | 99,660,050 | H Sh | 30.04% | 35.58% | 2026/06/24 | | Wang Bing | 44,400,000 | NON-H SHS | 13.38% | 85.93% | 2026/06/24 | | The People's Government of Shaanxi Province | 35,295,900 | H Sh | 10.64% | 12.60% | 2026/06/24 | | Suzhou Mainiv Venture Investment Partnership (Limited Partnership) | 27,333,350 | H Sh | 8.24% | 9.76% | 2026/06/24 | | Beta Achieve Limited | 17,733,350 | H Sh | 5.35% | 6.33% | 2026/06/24 | | The People's Government of Shaanxi Province | 7,269,250 | NON-H SHS | 2.19% | 14.07% | 2026/06/24 |
|
|
|
|
|